Edition:
United Kingdom

Swedish Orphan Biovitrum AB (publ) (SOBIV.ST)

SOBIV.ST on Stockholm Stock Exchange

199.25SEK
3:40pm GMT
Change (% chg)

8.60kr (+4.51%)
Prev Close
190.65kr
Open
191.95kr
Day's High
199.65kr
Day's Low
189.50kr
Volume
726,861
Avg. Vol
987,945
52-wk High
299.60kr
52-wk Low
110.55kr

Chart for

About

Swedish Orphan Biovitrum publ AB is a Sweden-based pharmaceutical company. The Company develops, manufactures and sells medications within hemophilia, autoimmune diseases, metabolic diseases and cancer supportive care. The Company’s product portfolio is divided into three business segments: the Core Products segment offers... (more)

Overall

Beta: 1.57
Market Cap(Mil.): kr34,172.46
Shares Outstanding(Mil.): 272.51
Dividend: --
Yield (%): --

Financials

  SOBIV.ST Industry Sector
P/E (TTM): 46.65 31.13 34.40
EPS (TTM): 2.69 -- --
ROI: 8.68 15.55 14.96
ROE: 12.91 16.92 16.53

BRIEF-FDA Approves Gamifant For Primary Hemophagocytic Lymphohistiocytosis

* FDA APPROVES GAMIFANT® (EMAPALUMAB-LZSG), THE FIRST AND ONLY TREATMENT INDICATED FOR PRIMARY HEMOPHAGOCYTIC LYMPHOHISTIOCYTOSIS (HLH)

20 Nov 2018

CORRECTED-Sweden's Sobi buys rights for emapalumab drug, strengthening inflammation business

STOCKHOLM, July 20 Drugmaker Swedish Orphan Biovitrum (Sobi) said on Friday it had reached an exclusive licensing deal with Swiss firm Novimmune SA for the perpetual global rights to emapalumab, a late-stage orphan drug candidate for the treatment of primary Haemophagocytic lymphohistiocytosis.

20 Jul 2018

Earnings vs. Estimates